Literature DB >> 34268252

Differential Expression and Prognostic Significance of STARD3 Gene in Breast Carcinoma.

Abdul Fattah Salah Fararjeh1, Ali Al Khader2,3, Ezidin Kaddumi4, Maher Obeidat1, O'la Al-Fawares1.   

Abstract

StAR related lipid transfer domain containing 3 (STARD3) gene has been reported to be co-amplified with human epidermal growth factor receptor 2 (HER2) in breast carcinoma. STARD3 is necessary for cholesterol transfer and metabolism in tumor cells. The possible role played by STARD3 as a diagnostic and prognostic biomarker was investigated in breast cancer (BC). Data mining was performed using several bioinformatics websites to investigate the correlation of STARD3 with BC and its molecular subtypes, and conventional PCR was used to detect the STARD3 mRNA levels in a panel of BC cell lines. STARD3 was overexpressed in BC more than the other types of cancer. The results also showed that STARD3 expression was significantly associated with HER2+ BC tumors and BC cell lines, and low STARD3 mRNA and protein expression levels were observed in estrogen receptor-positive (ER+) and triple-negative BC (TNBC) patients. Moreover, high STARD3 expression levels predicted worse overall survival (OS), relapse-free survival (RFS) and disease metastasis-free survival (DMFS) in BC, and HER2+ BC. Notably, low expression of STARD3 was associated with poor OS in ER+ BC. Our findings suggest that STARD3 may have strong diagnostic and prognostic value for HER2+ breast carcinoma.

Entities:  

Keywords:  Breast neoplasm; HER2; STARD3; computational biology; prognosis

Year:  2021        PMID: 34268252      PMCID: PMC8256830          DOI: 10.22088/IJMCM.BUMS.10.1.34

Source DB:  PubMed          Journal:  Int J Mol Cell Med        ISSN: 2251-9637


  28 in total

1.  Structure and lipid transport mechanism of a StAR-related domain.

Authors:  Y Tsujishita; J H Hurley
Journal:  Nat Struct Biol       Date:  2000-05

2.  Elevated levels of StAR-related lipid transfer protein 3 alter cholesterol balance and adhesiveness of breast cancer cells: potential mechanisms contributing to progression of HER2-positive breast cancers.

Authors:  Boris Vassilev; Harri Sihto; Shiqian Li; Maarit Hölttä-Vuori; Jaakko Ilola; Johan Lundin; Jorma Isola; Pirkko-Liisa Kellokumpu-Lehtinen; Heikki Joensuu; Elina Ikonen
Journal:  Am J Pathol       Date:  2015-02-12       Impact factor: 4.307

Review 3.  ERBB receptors and cancer: the complexity of targeted inhibitors.

Authors:  Nancy E Hynes; Heidi A Lane
Journal:  Nat Rev Cancer       Date:  2005-05       Impact factor: 60.716

Review 4.  HER2-positive breast cancer.

Authors:  Sibylle Loibl; Luca Gianni
Journal:  Lancet       Date:  2016-12-07       Impact factor: 79.321

5.  RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes.

Authors:  Jessica Kao; Jonathan R Pollack
Journal:  Genes Chromosomes Cancer       Date:  2006-08       Impact factor: 5.006

6.  Expression of MLN64 influences cellular matrix adhesion of breast cancer cells, the role for focal adhesion kinase.

Authors:  Wei Cai; Lin Ye; Jiabang Sun; Robert E Mansel; Wen G Jiang
Journal:  Int J Mol Med       Date:  2010-04       Impact factor: 4.101

7.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

Review 8.  Cholesterol and breast cancer development.

Authors:  Christiane Danilo; Philippe G Frank
Journal:  Curr Opin Pharmacol       Date:  2012-08-03       Impact factor: 5.547

9.  Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.

Authors:  Teemu T Junttila; Robert W Akita; Kathryn Parsons; Carter Fields; Gail D Lewis Phillips; Lori S Friedman; Deepak Sampath; Mark X Sliwkowski
Journal:  Cancer Cell       Date:  2009-05-05       Impact factor: 31.743

10.  Proteasome 26S Subunit, non-ATPase 3 (PSMD3) Regulates Breast Cancer by Stabilizing HER2 from Degradation.

Authors:  Abdulfattah Salah Fararjeh; Li-Ching Chen; Yuan-Soon Ho; Tzu-Chun Cheng; Yun-Ru Liu; Hang-Lung Chang; Hui-Wen Chang; Chih-Hsiung Wu; Shih-Hsin Tu
Journal:  Cancers (Basel)       Date:  2019-04-12       Impact factor: 6.639

View more
  3 in total

1.  Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression.

Authors:  Giorgia Centonze; Dora Natalini; Alessio Piccolantonio; Vincenzo Salemme; Alessandro Morellato; Pietro Arina; Chiara Riganti; Paola Defilippi
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

Review 2.  Therapeutic Potential of Thymoquinone in Triple-Negative Breast Cancer Prevention and Progression through the Modulation of the Tumor Microenvironment.

Authors:  Getinet M Adinew; Equar Taka; Bereket Mochona; Ramesh B Badisa; Elizabeth A Mazzio; Rashid Elhag; Karam F A Soliman
Journal:  Nutrients       Date:  2021-12-25       Impact factor: 5.717

Review 3.  Linking Late Endosomal Cholesterol with Cancer Progression and Anticancer Drug Resistance.

Authors:  Mai K L Nguyen; Jaimy Jose; Mohamed Wahba; Marc Bernaus-Esqué; Andrew J Hoy; Carlos Enrich; Carles Rentero; Thomas Grewal
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.